Early diagnosis means early intervention

Clarifi is a clinically-validated test aiding in the diagnosis of autism spectrum disorder.

Clarifi in the news, Clarifi ASD autism saliva test, news, studies, research news

Clarifi in the news

The Clarifi autism
saliva test

The Clarifi test is designed to provide a probability of an autism diagnosis based on epigenetic biomarkers in the saliva. It is currently available to children 18 months through 6 years of age.

non invasive autism test, saliva test for autism

Non-invasive and easily administered saliva test

Clarifi autism saliva test, rapid results, fast results, results in 3 to 6 weeks

Accelerates the diagnostic process with results in 3 to 6 weeks

Clarifi, Clarifi autism saliva test, clinically validated

Peer-reviewed research and clinically validated

epigenetic saliva test for autism, autism saliva test, epigenetic autism test, Clarifi autism test

Measures epigenetic molecules in saliva

Is your child eligible for Clarifi?

Clarifi is currently available to children who meet the following eligibility requirements.

Suspicion of autism

For children with a clinical suspicion of autism, such as a positive screen on MCHAT-R

Appropriate age range

Must be 18 months through 6 years of age

Meets geographic requirements

Clarifi is currently available in the U.S., excluding New York State

Ready to talk to your child’s health care provider about Clarifi?

The road to Clarifi

Read about our team’s journey to find a science based diagnostic tool for autism spectrum disorder.


Rising autism prevalence and
longer wait times for diagnosis

According to the CDC, 1 in 59 children in the U.S. are diagnosed with ASD. Even though ASD can be clinically diagnosed as early as 2 years, the average age of diagnosis is currently 4 years of age. A biological tool aiding in the diagnosis of ASD can expedite the diagnostic process.


“There has clearly been an increase in prevalence of autism spectrum disorder in our society. Our goal is to facilitate diagnosis in younger children and maximize the potential for interventions to improve abilities, outcomes and quality of life.”

Randall Carpenter, MD
Executive Vice President Clinical Development at Quadrant Biosciences


Cutting-edge breakthroughs in epigenetic research

Clarifi is not a genetic test. It is the product of game-changing scientific advancements in the area of epigenetics; the factors that influence how genes are turned on and off. Our peer-reviewed research discovered that certain RNA molecules that regulate genetic activity and reflect interactions between a patient and their environment, were different in children with autism.

“In too many cases children may not receive a diagnosis until they are 5 years old. Early diagnosis is critical for children with autism, and primary care providers play an important role in that initial process.”

Kristin Sohl, MD, FAAP
Associate Professor, Clinical Child Health – Vice Chair for Quality Improvement, Child Health Department – Advocacy Director, Child Health Department – Director, ECHO Autism
Translating the science into practical solutions


Translating the science into practical solutions

The next step was turning this breakthrough technology into a publicly available test. To accomplish this, Admera Health, a CLIA-certified Laboratory, developed and validated the Clarifi test by incorporating Quadrant Biosciences’ unique bioinformatics platform.


First ever epigenetic
test for autism

Clarifi can be used in children with a clinical suspicion or positive screen for autism (e.g., M-CHAT-R), to help determine the urgency of a specialist referral. In children with more obvious autism symptoms, a positive Clarifi test may give health care providers the confidence necessary to diagnose a child with autism and start beneficial therapies earlier.

First ever objective epigenetic test for autism

“A test which can separate children who have screened M-CHAT positive into high likelihood of autism or low likelihood of autism could help streamline waitlists and permit earlier diagnosis and enrollment in autism treatment.”

Dr. Daniel Coury MD
Professor of Pediatrics and Psychiatry at College of Medicine at The Ohio State University and the Section of Developmental and Behavioral Pediatrics for Nationwide Children’s Hospital
Diagnosis is only the first step


Diagnosis is only the first step

Quadrant Biosciences is proud to support Autism Speaks in providing resources and solutions to individuals and families touched by autism. In your patient account, you will find links to resources such as toolkits, local service provider directories and other helpful information.
Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the lifespan, for the needs of individuals and their families.


We’ve partnered with top
research and support organizations

Quadrant Biosciences is privileged to be aligned with a number of top autism research and support organizations


“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”

Richard Uhlig Founder and CEO
Quadrant Biosciences Inc.


Interested in getting your child tested? Download, print, and bring this information to your child’s health care provider.

Health care providers

Ready to offer Clarifi to your patients? Get started by completing the online application.

Clarifi ASD is now available

Stay up to date with news and announcements